Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial
| Autor: | Daniel P. Rossignol, Melvyn Lynn, Kenneth Krell, Mary B. Roberts, Jean-Paul Mira, Janice L. Wheeler, Luis Jauregui, Mark Tidswell, Dominique Perrotin, Jan Pachl, Xavier Wittebole, Takahashi Takeshi, Derek C. Angus, Roland M. H. Schein, Jagadish Gogate, Edward Cordasco, Steven P. LaRosa, Andre C. Kalil, Jean Louis Vincent, Tatsuya Maruyama, Marc Van Nuffelen, Bruno François, Claus Peckelsen, Thierry Dugernier, Chia-Sheng Chang, Sandra Oeyen, Pierre-François Laterre, Naoki Aikawa, Steven M. Opal |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Organ Dysfunction Scores Secondary infection TETRASODIUM E5564 INHIBITION UNITED-STATES Kaplan-Meier Estimate LIPOPOLYSACCHARIDE Disaccharides Placebo Severity of Illness Index law.invention CLINICAL-TRIAL Young Adult chemistry.chemical_compound Double-Blind Method Randomized controlled trial law Sepsis Internal medicine Intensive care medicine Medicine and Health Sciences Humans Eritoran Aged Aged 80 and over RECEPTOR 4 Septic shock business.industry Mortality rate Hazard ratio SEPTIC SHOCK General Medicine Middle Aged medicine.disease Surgery Toll-Like Receptor 4 chemistry ENDOTOXIN RESPONSE Female Sugar Phosphates business GRAM-NEGATIVE BACTEREMIA HEALTHY-VOLUNTEERS |
| Zdroj: | JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION |
| ISSN: | 0098-7484 |
| Popis: | Importance Eritoran is a synthetic lipid A antagonist that blocks lipopolysaccharide (LPS) from binding at the cell surface MD2-TLR4 receptor. LPS is a major component of the outer membrane of gram-negative bacteria and is a potent activator of the acute inflammatory response. Objective To determine if eritoran, a TLR4 antagonist, would significantly reduce sepsis-induced mortality. Design, Setting, and Participants We performed a randomized, double-blind, placebo-controlled, multinational phase 3 trial in 197 intensive care units. Patients were enrolled from June 2006 to September 2010 and final follow-up was completed in September 2011. Interventions Patients with severe sepsis (n = 1961) were randomized and treated within 12 hours of onset of first organ dysfunction in a 2:1 ratio with a 6-day course of either eritoran tetrasodium (105 mg total) or placebo, with n = 1304 and n = 657 patients, respectively. Main Outcome Measures The primary end point was 28-day all-cause mortality. The secondary end points were all-cause mortality at 3, 6, and 12 months after beginning treatment. Results Baseline characteristics of the 2 study groups were similar. In the modified intent-to-treat analysis (randomized patients who received at least 1 dose) there was no significant difference in the primary end point of 28-day all-cause mortality with 28.1% (366/1304) in the eritoran group vs 26.9% (177/657) in the placebo group (P = .59; hazard ratio, 1.05; 95% CI, 0.88-1.26; difference in mortality rate, −1.1; 95% CI, −5.3 to 3.1) or in the key secondary end point of 1-year all-cause mortality with 44.1% (290/657) in the eritoran group vs 43.3% (565/1304) in the placebo group, Kaplan-Meier analysis of time to death by 1 year, P = .79 (hazard ratio, 0.98; 0.85-1.13). No significant differences were observed in any of the prespecified subgroups. Adverse events, including secondary infection rates, did not differ between study groups. Conclusions and Relevance Among patients with severe sepsis, the use of eritoran, compared with placebo, did not result in reduced 28-day mortality. Trial Registration clinicaltrials.gov Identifier: NCT00334828 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|